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Objectives This multicenter study sought to evaluate the long-term follow-up of patients ablated for idiopathic ventricular
fibrillation (VF).
Background Catheter ablation of idiopathic VF that targets ventricular premature beat (VPB) triggers has been shown to pre-
vent VF recurrences on short-term follow-up.
Methods From January 2000, 38 consecutive patients from 6 different centers underwent ablation of primary idiopathic
VF initiated by short coupled VPB. All patients had experienced at least 1 documented VF, with 87% having ex-
perienced 2 VF episodes in the preceding year. Catheter ablation was guided by activation mapping of VPBs or
pace mapping during sinus rhythm.
Results There were 38 patients (21 men) age 42  13 years, refractory to a median of 2 antiarrhythmic drugs. Triggering
VPBs originated from the right (n  16), the left (n  14), or both (n  3) Purkinje systems and from the myocar-
dium (n  5). During a median post-procedural follow-up of 63 months, 7 (18%) of 38 patients experienced VF recur-
rence at a median of 4 months. Five of these 7 patients underwent repeat ablation without VF recurrence. Survival
free of VF was predicted only by transient bundle-branch block in the originating ventricle during the electrophysiologi-
cal study (p  0.0001). The number of significant events (confirmed VF or aborted sudden death) was reduced from
4 (interquartile range 3 to 9) before to 0 (interquartile range 0 to 4) after ablation (p  0.01).
Conclusions Ablation for idiopathic VF that targets short coupled VPB triggers is associated with a long-term freedom from VF
recurrence. (J Am Coll Cardiol 2009;54:522–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.065d
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ientricular fibrillation (VF) is the main cause of sudden
ardiac death, which is responsible for approximately
00,000 deaths in U.S. alone (1). Although most of these
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rugmann, Brussels, Belgium; and the §§Lariboisière Hospital, Paris, France. Dr.
necht is supported by the Belgian Foundation for Cardiac Surgery. Bruce Lindsay,
D, served as Guest Editor for this article.e
Manuscript received December 8, 2008; revised manuscript received February 20,
009, accepted March 3, 2009.eaths are associated with identifiable causes such as isch-
mic heart disease and cardiomyopathy (2), idiopathic VF
till accounts for up to 8% of victims of sudden cardiac death
3) and represents a major health care issue.
See page 529
The gold standard treatment for either primary or sec-
ndary prevention of VF is the insertion of an implantable
ardiac-defibrillator (ICD) (2,4–7). However, although an
CD can deliver life-saving therapy at the time of an event,
t does not prevent the event from occurring. Previous
xperimental and clinical studies have demonstrated the
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August 4, 2009:522–8 Long-Term Follow-Up of Idiopathic VF Ablationmportance of the Purkinje network in the initiation of VF
8–14). Ablation targeting specific Purkinje potentials that
recede the culprit ventricular premature beat (VPB) has
hown encouraging short-term results (9–12,15). However,
he long-term outcomes of patients after VF ablation are
till unknown. Therefore, we sought to evaluate the long-
erm effect of targeted ablation of triggering VPB in patients
ith VF.
ethods
tudy population. From January 2000, 38 consecutive
atients from 6 centers underwent attempted ablation of
rimary idiopathic VF. Only patients with primary idio-
athic VF without preceding monomorphic ventricular
achycardia were included. Patients were recruited if they
ad experienced at least 1 significant event (either syncope,
lectrical storm, documented VF, or aborted sudden cardiac
eath) with documented VPB-triggered VF on a 12-lead
lectrocardiogram (ECG). The definition of idiopathic VF
as based on established criteria, including a normal phys-
cal examination and ECG, echocardiography, and right
nd left ventricular ejection fraction in all patients (16).
tructural heart disease, myocardial ischemia, and cat-
cholaminergic ventricular tachycardia (VT) were excluded
y clinical history, Holter monitoring, exercise testing,
oronary angiography, and infusion of isoproterenol and/or
drenaline in all patients as previously described (9). Fur-
hermore, endomyocardial biopsy was performed in 8 pa-
ients and egonovine infusion in 7 patients. Abnormalities
f ventricular repolarization were excluded in all patients
ased upon a corrected QT interval between 340 and 440
s and the absence of QT prolongation after a pause by
se of the Bazett formula. Brugada syndrome was ex-
luded by normal QRST complexes in V1 to V3 leads in
ll ECGs before and after cardiac arrest and during oral
r intravenous class IC drug administration in 24 pa-
ients. Channelopathies were excluded by genetic testing
n 14 patients.
lectrophysiological study. We attempted to perform an
nvasive electrophysiology study during electrical storm.
f this was not possible, patients were studied soon
fterward or at a time of frequent VPBs. Multielectrode
atheters (2 to 4) were introduced percutaneously
hrough the femoral veins, including a 4-mm tip ablation
atheter (Biosense Webster, Diamond Bar, California).
urface ECG leads and bipolar intracardiac electrograms
ltered at 30 to 500 Hz were recorded simultaneously
ith a polygraph (model Lab system or Midas, 1- to
-kHz and 10-kHz sampling rate, respectively, or Bard
lectrophysiology, Lowell, Massachusetts) for off-line
nalysis. When left ventricular access was required, it was
btained by the transseptal or retrograde aortic method.
fter transseptal access, a single bolus of heparin (30
U/kg) was administered.
blation protocol. The procedural end point was abolition
f all clinical VPBs. These VPBs were localized by mapping
he earliest electrogram relative to the onset of the ectopic QRS somplex during a ventricular ec-
opy. During sinus rhythm, the
ocation of the Purkinje network
as indicated by initial sharp po-
entials (10 ms in duration) pre-
eding the QRS complex by 15
s. Such electrograms were dis-
inct from earlier electrograms
15 ms before the QRS) that
ere taken to indicate proximal
urkinje fascicle activation. The
bsence of a Purkinje potential at
he site of earliest activation indicated the ventricular myocar-
ium as the origin of the VPB.
If required, VPBs were induced by the use of pacing
aneuvers (ventricular burst or extrastimuli) and/or isopro-
erenol (1 to 4 g/kg/min) or adenosine (up to 40 mg) by
ntravenous infusion. If these measures were ineffective,
ace mapping was used to identify the site of origin of
linical VPBs (perfect match of at least 11/12 leads on the
urface ECG).
Ablation was performed by the use of radiofrequency
nergy with a target temperature of 50°C and a maximum
ower of 50 W. In cases in which the desired power could
ot been delivered, an externally irrigated 3.5-mm tip
atheter (Thermocool, Biosense Webster) was used. For
his purpose, manual titration of the saline perfusate
anging from 10 to 60 ml/min was performed to achieve
he required power. In all cases, ablation was extended
pproximately 1 cm2 around the targeted site. No
-dimensional mapping system was used during the
blation protocol.
ollow-up. All recruiting centers were contacted for each
atient, and follow-up was completed by August 2008. In
ddition to records of clinical events, ECGs, and Holter
onitoring, VF and associated intracardiac electrograms
ere documented by ICD interrogation. Thirty-seven of 38
atients received an ICD in the periablation period; 1
atient refused ICD implantation after ablation. Antiar-
hythmic drugs were generally ceased after ablation except
n the case of VF recurrence and unless otherwise decided by
he referring cardiologist. A repeat ablation procedure was
ndertaken in the event of VF recurrence refractory to
ntiarrhythmic medication.
tatistical analysis. Continuous variables are expressed as
ean  SD except for count and time variables, which are
xpressed as median and the interquartile range (IQR).
tatistical significance was assessed by use of the unpaired
tudent t test or Mann-Whitney U test if necessary.
ategorical variables, expressed as numbers or percentages,
ere analyzed with the chi-square test or Fisher exact test.
ifferences between baseline and after VF ablation were
ested by the paired Student t test or Wilcoxon signed rank
est for continuous variables. Univariate analysis of variables
as performed. A p value 0.05 was considered statistically
Abbreviations
and Acronyms
ICD  implantable
cardiac-defibrillator
IQR  interquartile range
VF  ventricular fibrillation
VPB  ventricular
premature beat
VT  ventricular
tachycardiaignificant.
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opulation study. We studied 38 patients (21 men) ages
2  13 years. In sinus rhythm, the mean heart rate was
8  10 beats/min, and ECG results showed a PR
nterval of 164  24 ms, a QRS duration of 92  15 ms,
nd a corrected QT interval of 398  25 ms. The left
entricular ejection fraction was 67  9%, and the left
entricular end-diastolic dimension was 42  10 mm.
efore ablation, patients were refractory to a median of 2
IQR 1 to 3) antiarrhythmic drugs. The median number of
ignificant events before ablation was 4 (IQR 3 to 9) events.
he median time from the first significant ventricular event
Figure 1 Triggered VF
Twelve-lead electrocardiograms (left) and their corresponding location in the anter
beat (VPB) triggering ventricular fibrillation (VF) was the left Purkinje either at the p
lar outflow track (D). Related fluoroscopic views with a decapolar catheter inserted
(G), and a quadripolar catheter inserted at the His position (E to G). Ventricular p
rior fluoroscopic view) produce more variable 12-lead electrocardiogram (ECG) patt
originating in the right Purkinje system (C and related anteroposterior fluoroscopic
lar premature beat originating from the right ventricular outflow track (D) have the
aseline Characteristics ofti nts Undergoing AblationTable 1 B seline Ch racteristics ofPatients Undergoing Ablation
Age (yrs) 42 13
Sex (male) 21/38 (55%)
Left ventricular ejection fraction (%) 67 9
Left ventricular end-diastolic diameter (mm) 42 10
Implantable cardiac-defibrillator 37/38 (97%)
Time from initial VF to ablation (months) 4 (IQR 1–36)
Number of significant events before ablation 4 (IQR 3–9)
Antiarrhythmic medication before ablation 2 (IQR 1–3)
Coupling interval of VPB (ms) 291 39
QR  interquartile range; VF  ventricular fibrillation; VPB  ventricular premature beat.o ablation was 4 months (IQR 1 to 36 months). Thirty-
hree of the 38 patients (87%) had at least 2 events in the
ear before the initial ablation procedure. The coupling
nterval of VPB was longer when originating from the right
entricular outflow tract compared with the Purkinje system
355  23 ms vs. 276  22 ms, p  0.001). Clinical
haracteristics are summarized in Table 1.
blation procedure. The median duration of radiofre-
uency energy delivered, fluoroscopy, and total ablation
rocedural time were 14 min (IQR 9 to 24 min), 28 min
IQR 18 to 52 min) and 135 min (IQR 100 to 215 min),
espectively. Thirty patients (81%) had clinical VPB at the
ime of the procedure, whereas 8 patients (19%) did not.
linical VPBs triggering VF arose from the right Purkinje
ystem in 16 patients, the left Purkinje in 14 patients, in
oth the left and right Purkinje system in 3 patients, and in
he myocardium in 5 patients (including the right ventric-
lar outflow track in 4 patients) (Fig. 1). A mean of 1.7 
.0 VPB morphologies were targeted per patient. The QRS
uration of VPBs was shorter when originating from the left
han the right Purkinje system (130  24 ms vs. 162  19
s, p  0.002), but the QRS duration of VPBs was not
ignificantly different between VPBs originating from the
eft Purkinje system and the myocardium (130  24 ms vs.
50  16 ms, respectively, p  0.11). When VPBs were
rior fluoroscopic view (right, red asterisks). The origin of ventricular premature
r (A) or the anterior (B) insertion, the right Purkinje (C), and the right ventricu-
left ventricle (E and F), an ablation catheter inserted in the right ventricle
re beat originating in the left Purkinje system (A and B and related anteroposte-
eflecting the more complex and extended Purkinje arborization on the left. VPBs
typically have a left bundle-branch block pattern with left superior axis. Ventricu-
cal aspect with a left bundle-branch block pattern and an inferior axis.oposte
osterio
in the
rematu
erns, r
view)
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August 4, 2009:522–8 Long-Term Follow-Up of Idiopathic VF Ablationresent at the time of the procedure, catheter ablation was
uccessful in abolishing VPB in all patients.
Ablation at successful sites typically resulted in multiple
PBs leading to polymorphic VT and/or VF (Fig. 2). After
blation, 1 patient developed transient left bundle-branch
lock. Six other patients developed nonspecific intraventric-
lar conduction defects not meeting formal criteria for a
undle-branch block.
esults on clinical follow-up. During a median follow up
f 63 months (IQR 40 to 80 months), 7 (18%) of 38
atients experienced a recurrence of VF. This occurred after
median of 24 months (IQR 1 to 60 months). VF
ecurrence was detected by the ICD and did not lead to
yncope or clinical sudden cardiac arrest in any of the
atients. Ablation was repeated in 5 of these 7 patients (1
atient had 2 repeat procedures). Four of these 5 patients
ad other VPB morphologies as compared with the initial
rocedure, whereas 1 patient had the same clinical VPB
ecurrence triggering VF. These 5 patients had no subse-
uent recurrence of VF or documented VPBs for 28 months
IQR 24 to 72 months).
Two patients with VF recurrence were not reablated.
n these 2 patients, clinical VPB morphology triggering
F recurrence could not be analyzed because there was
o 12-lead ECG recording of the events. Of these 2
Figure 2 12-Lead Electrocardiogram During Radiofrequency Abl
The start of ablation (arrow) typically resulted in ventricular tachycardia followed batients, 1 was treated with quinidine. This treatment
ad been ineffective before ablation and was discontinued
ithout medical advice after ablation; after reinitiation of
uinidine, there have been no VF recurrences (for 6
onths). The second patient who did not receive reab-
ation had a single asymptomatic short run of polymor-
hic VT 2 years after the ablation, which terminated
pontaneously (without ICD therapy) and which did not
ecur for 5 years.
Before ablation, 12 patients (32%) experienced VF elec-
rical storm 3 months (IQR 1 to 6 months) beforehand,
hereas after ablation, only 3 patients (8% of all patients)
ad a recurrence of electrical storm (p 0.03) that occurred
, 48, and 60 months after ablation. Three patients experi-
nced clinical recurrence of the initial clinical VPB after the
nitial ablation procedure, which did not result in malignant
entricular arrhythmia. One symptomatic patient has been
eablated without recurrence of VPB, and the 2 other
atients never experienced malignant ventricular arrhythmia
ecurrence on verapamil and quinidine therapy despite
ersistence of VPB.
verall results for this strategy. Ablation significantly
educed the number of significant events (confirmed VF/VT
r sudden death) from 4 (IQR 3 to 9) before ablation to 0
total range 0 to 4, p  0.01) afterwards. After a mean
at the Right Purkinje System
s rhythm, as shown in this example.ation
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Long-Term Follow-Up of Idiopathic VF Ablation August 4, 2009:522–8ollow-up of 52  28 months after the last procedure, 36 of
8 patients are free from VF after a mean of 1.28  0.6
rocedures. Five (13%) of the 38 patients are currently on
ntiarrhythmic therapy, including 2 who experienced VF
ecurrence and 2 with VPB recurrence.
redictors of VF recurrence. The only parameter that was
ssociated with an adverse outcome was the presence of
undle-branch block in the targeted ventricle before abla-
ion as the result of mechanical trauma “bumping” (p 
.0001; hazard ratio: 0.0325, 95% confidence interval:
.00001 to 0.00006) (Fig. 3). Technically, this is related to
he fact that such bundle-branch block obscured ipsilateral
urkinje potentials during sinus rhythm, thus complicating
ubsequent ablation. Notably, the frequency of VPB at the
ime of EP study and a greater frequency of previous events
id not predict adverse outcome in this study.
iscussion
ain findings. This multicenter study confirms that abla-
ion for idiopathic VF, targeted at its potential ventricular
ctopic triggers, may effectively prevent VF recurrence in a
igh-risk population. With rigorous follow-up for more
han 5 years, with the use of both clinical information and
ata from ICD interrogations in all but 1 patient, we found
hat only 18% of individuals had a recurrence of VF or
olymorphic VT. In these patients in whom structural
isease and other proarrhythmic syndromes had been ex-
luded, the only parameter that predicted ablation success
as ipsilateral intraventricular conduction delay at electro-
hysiological study.
blation of VF. The feasibility of VF ablation has already
een demonstrated in populations with idiopathic VF (9),
Figure 3 Example of a Mechanical Trauma “Bumping” of the R
A mechanical trauma “bumping” of the right bundle branch results in a typical right bu
of the Purkinje potential (asterisks), which is activated retrogradely and therefore obsong-QT syndrome, Brugada syndrome, and ischemic heart
isease (10–12,15). Although mechanisms for VF have yet
o be defined for each syndrome, the basis may be scar and
e-entry in ischemic disease (17), focal ectopy and re-entry
n the long-QT syndrome (18), and conduction slowing
19) with repolarization dispersion (20) in Brugada syn-
rome. Patients with idiopathic VF, such as those in our
tudy, lack many of these substrates. Indeed, increasing
vidence suggests that the Purkinje network may have a
rimary role in both initiating and perpetuating VF in these
atients (8,9,21).
ole of the Purkinje network in idiopathic VF. The
pecialized conduction system of the Purkinje network,
ocalized endocardially in the human heart, consists of a
ingle branch on the right that penetrates a limited portion
f the right ventricle, and 2 larger branches on the left that
amify more intricately to supply a greater area of the left
entricle (22,23). There is a growing body of evidence that
he Purkinje network plays a pivotal role in both the
nitiation and perpetuation of VF. In experiments per-
ormed in isolated canine hearts, multielectrode mapping of
he endocardial left ventricle have shown a focal initiating
echanism for VF in 34% of cases, of which 42% arose
rom Purkinje fibers (24). Moreover, endocardial activation
nvolved the Purkinje network in 84% of cases (24). The
urkinje system has been shown to be capable of very rapid
urst activity suggestive of its potential role in being a driver
f VF (9). Finally, studies also suggest the existence of
e-entry involving the Purkinje-myocardial junction, at least
n the early stages of VF (8).
In a previous multicenter study, conduction delay from
he Purkinje network to the myocardium were shorter in the
undle-Branch Before Ablation
ranch pattern on the 12-lead electrocardiogram and the disappearance
y the ventricular complex. The third QRS complex is indicted by the arrow.ight B
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August 4, 2009:522–8 Long-Term Follow-Up of Idiopathic VF Ablationight than left ventricle, with variable conduction delays and
issociated Purkinje potentials in some patients (9). Ectopy
rising from the Purkinje system produces a characteristic
2-lead ECG pattern; VPBs originating in the right Pur-
inje system typically have a left bundle-branch block
attern with left superior axis. Ventricular premature beats
riginating in the left Purkinje system produce more vari-
ble 12-lead ECG patterns, reflecting the more complex
nd extended Purkinje arborization on the left (Fig. 1).
ractical considerations for ablation. A previous report
uggested that the success of VF ablation improves when
atients have clinical ectopy at the time of the procedure (9),
et the absence of frequent VPB at the time of ablation did
ot predict an unfavorable outcome in our study. Neverthe-
ess, when clinical VPBs are infrequent or absent at the time
f the procedure, localizing the Purkinje network remains of
rimary importance for procedural success. Notably, ipsilat-
ral intraventricular conduction delay was the only indepen-
ent predictor of success because once this occurs, it masks
psilateral Purkinje potentials in sinus rhythm. The speci-
city of this index awaits further study.
Interestingly, a recurrence of clinical VPBs was observed
n 2 patients that no longer resulted in malignant ventricular
rrhythmia despite the extended follow-up. Speculatively,
his finding suggests that modulation of the Purkinje system
nd its surrounding tissue may be sufficient in some cases to
void VF initiation.
linical implications. Implantation of a cardiac defibrilla-
or is the gold standard treatment for both primary and
econdary prevention of sudden cardiac death (2,4–7).
lthough the long-term results of the present study are very
ncouraging, ablation of triggering VPBs for VF does not
eplace ICD implantation. This finding is re-enforced by
he present study because some patients who had a recur-
ence of VF had a new morphology of VPB triggering VF,
uggesting an evolution of the disease for these patients.
owever, repeated ICD shocks for electrical storm may
ccur in 10% to 25% of patients (25,26). Because ICD
herapy may not fully protect against VF and electrical
torm (27,28), adjunctive VF ablation may be useful in
educing mortality in patients with recurrent VF. Moreover,
CD therapy has its drawbacks. The use of ICDs does not
rovide absolute protection against death due to ventricular
rrhythmia, with a risk for sudden death among patients
ho do not have a response to ICDs of approximately 5%
29). In addition, ICD discharges are painful, whereas
yncope may occur before delivery of a shock. Clinically
ignificant anxiety and depression as a result of recurrent
CD shocks occur in 50% of patients (30–32).
The results of this study demonstrate the feasibility of
atheter ablation for patients with idiopathic VF, targeting
hort coupled VPBs that may trigger arrhythmogenic epi-
odes. This strategy may reduce the morbidity of patients
ith idiopathic VF implanted with an ICD. It may also
ecrease the mortality from arrhythmic storm for these
atients, although this requires further prospective trials.tudy limitations. This is an observational study with no
ontrol group; however, this was a high-risk population that
xperiences multiple events and that has been shown to be
ssociated with a poor outcome (26,27). Another important
imitation is the fact that VF episodes are sporadic, and it is
ifficult to state with certainty that the absence of VF
ecurrence was due to ablation. However, the patients in the
tudy had frequent clinical events before ablation, yet very
ew afterwards, rendering this criticism less important.
evertheless, further studies with a control group of ICD
ecipients without adjunctive ablation would help to address
his issue prospectively. Third, it is impossible to exclude the
mpact of additional antiarrhythmic agents in suppressing
he arrhythmias. However, all patients had already failed
ntiarrhythmic medications, whereas multivariate analysis
ailed to reveal that post-ablation drug was a confounder.
ecause of the often-dramatic presentation of these pa-
ients, it was difficult to implement uniform ICD program-
ing between centers. However, by definition, idiopathic
F was not preceded by VT. Furthermore, in the 7 patients
ho experienced post-ablation recurrence, VF was not
receded by VT or by an acceleration of a tachycardia into
F by antitachycardia pacing.
onclusions
blation of idiopathic VF, targeted to its VPB triggers, is
easible and results in an excellent long-term outcomes.
hort coupled VPB triggering VF originates predominantly
rom the Purkinje system and the right ventricular outflow
rack.
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ervice de Rythmologie, Hôpital Cardiologique du Haut-Lévêque,
venue de Magellan, 33604 Bordeaux-Pessac, France. E-mail:
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